JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.'
The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families.
For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities.
Learn more about JCR, its technologies, and clinical development programs on its global website: https://jcrpharm.com/.
About the J-Brain Cargo ® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa).
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: https://jcrpharm.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
38 minutes ago
- Business Upturn
Hatton National Bank partners with Nucleus Software to upgrade transaction banking with FinnAxia®
By News Desk Published on July 30, 2025, 09:44 IST Nucleus Software Exports Ltd. has announced a strategic partnership with Hatton National Bank PLC (HNB), one of Sri Lanka's premier private banks, to enhance its transaction banking capabilities through the deployment of FinnAxia®, Nucleus's advanced transaction banking suite. The collaboration is aimed at helping HNB accelerate digital transformation, particularly in the areas of payments, cash management, and corporate banking services. The rollout of FinnAxia® is a key step in HNB's ambition to strengthen its leadership in the SME and corporate banking segments, both domestically and internationally. 'We are reimagining our transaction banking strategy to not only retain our leadership position in the payments and cash management space but to significantly expand our presence in the SME and corporate banking segments,' said Damith Pallewatte, Managing Director & CEO, HNB. 'FinnAxia® gives us the technology edge to offer a comprehensive, digital-first experience.' Since going live, HNB has reported a 10X increase in customer onboarding and a 6X jump in transaction volumes, showcasing early success of the implementation. The platform enables real-time dashboards, automated reconciliation, and enhanced visibility, which is critical for treasuries to make data-driven decisions. Vishnu R. Dusad, Managing Director and Co-Founder of Nucleus Software, stated: 'With FinnAxia®, we are not just delivering technology, but building a competitive advantage. Our partnership with HNB reflects a shared ambition to redefine digital transaction banking in Sri Lanka.' Ahmedabad Plane Crash News desk at
Yahoo
an hour ago
- Yahoo
Asian Stocks Estimated To Be 12.7% To 26.2% Below Intrinsic Value
As global markets respond to favorable trade deal news, Asian equities have shown resilience amid ongoing tariff discussions and economic uncertainties. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can offer potential opportunities for investors looking to capitalize on market inefficiencies. Top 10 Undervalued Stocks Based On Cash Flows In Asia Name Current Price Fair Value (Est) Discount (Est) Shin Maint HoldingsLtd (TSE:6086) ¥1174.00 ¥2321.82 49.4% Shenzhen KSTAR Science and Technology (SZSE:002518) CN¥23.34 CN¥46.18 49.5% Range Intelligent Computing Technology Group (SZSE:300442) CN¥51.15 CN¥101.32 49.5% Polaris Holdings (TSE:3010) ¥220.00 ¥433.40 49.2% Nan Ya Printed Circuit Board (TWSE:8046) NT$177.00 NT$350.10 49.4% LigaChem Biosciences (KOSDAQ:A141080) ₩139000.00 ₩277490.02 49.9% Hibino (TSE:2469) ¥2345.00 ¥4664.61 49.7% Heartland Group Holdings (NZSE:HGH) NZ$0.82 NZ$1.62 49.4% Forum Engineering (TSE:7088) ¥1206.00 ¥2405.10 49.9% Andes Technology (TWSE:6533) NT$274.50 NT$542.92 49.4% Click here to see the full list of 265 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Dongsung FineTec Overview: Dongsung FineTec Co., Ltd. is a South Korean company that manufactures and sells cryogenic insulation products, with a market cap of approximately ₩811.48 billion. Operations: The company's revenue segments include the Gas Business, generating approximately ₩23.03 billion, and Cooling Material, contributing around ₩609.47 billion. Estimated Discount To Fair Value: 26.2% Dongsung FineTec is trading at ₩27,950, significantly undervalued compared to its estimated fair value of ₩37,869.08. Its earnings are projected to grow at 22.6% annually, outpacing the Korean market's growth rate and reflecting robust financial health despite an unstable dividend track record. Recent quarterly results showed net income of KRW 9 billion, up from KRW 8.69 billion a year earlier, reinforcing its strong cash flow position in the Asian market. Our growth report here indicates Dongsung FineTec may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in Dongsung FineTec's balance sheet health report. Nanjing Vazyme Biotech Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics with a market cap of CN¥10.52 billion. Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in life science, biomedicine, and in vitro diagnostics. Estimated Discount To Fair Value: 17.1% Nanjing Vazyme Biotech is trading at CN¥26.44, slightly below its fair value estimate of CN¥31.91, suggesting it may be undervalued based on cash flows. The company is expected to become profitable within three years, with earnings projected to grow 78.27% annually—surpassing market averages despite a low forecasted return on equity of 5.6%. A recent share buyback plan worth CN¥10 million aims to enhance shareholder value through potential equity incentives or employee stock ownership plans. Our expertly prepared growth report on Nanjing Vazyme Biotech implies its future financial outlook may be stronger than recent results. Delve into the full analysis health report here for a deeper understanding of Nanjing Vazyme Biotech. Zhejiang Yinlun MachineryLtd Overview: Zhejiang Yinlun Machinery Co., Ltd. focuses on the research, development, manufacturing, and sale of thermal management and exhaust gas post-treatment products, with a market cap of CN¥24.97 billion. Operations: The company generates revenue primarily from the sale of thermal management and exhaust gas post-treatment products. Estimated Discount To Fair Value: 12.7% Zhejiang Yinlun Machinery is trading at CN¥30.13, undervalued relative to its fair value estimate of CN¥34.53. Earnings grew 18.9% last year and are projected to rise 25.12% annually, outpacing the Chinese market's growth rate of 23.5%. Despite a lower future return on equity forecast of 16.1%, recent share buybacks totaling CN¥34.96 million may enhance shareholder value through equity incentives or employee stock ownership plans. According our earnings growth report, there's an indication that Zhejiang Yinlun MachineryLtd might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of Zhejiang Yinlun MachineryLtd. Make It Happen Reveal the 265 hidden gems among our Undervalued Asian Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSDAQ:A033500 SHSE:688105 and SZSE:002126. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hypebeast
an hour ago
- Hypebeast
FreshService Presents a 'Heavy Duty' FW25 Collection
Summary FreshService'sFall/Winter 2025collection, titled 'Heavy Duty,' reinforces the brand's utilitarian design ethos with a heightened focus on durability, modularity and layered functionality. Led by creative director Takayuki Minami, the lineup draws from classic workwear silhouettes and reinterprets them through an urban-industrial lens. The result is a tightly curated collection that merges practical construction with minimalist aesthetics. Key pieces include the N/C Grosgrain Mountain Parka, waxed poplin fishing jackets and flannel check reversible vests — each designed for versatility and weather resistance. Complementing these are fleece zip-ups, corduroy utility pants and corporate denim five-pocket trousers, all rendered in subdued earth tones and designed with performance in mind. High-grade materials such as SOLOTEX® and PERTEX® Quantum Air further elevate the collection, reflecting FreshService's ongoing commitment to comfort and innovation. FreshService's FW25 offering is rounded out by an assortment of accessories such as flannel trapper caps, cotton twill bucket hats and multi-border tees lend texture and visual rhythm to the lineup. 'Heavy Duty' will be available to shop via the brand'sonlineand physical stores soon, with prices ranging from ¥3,000 – ¥42,000 JPY (approx. $20 – $284 USD).
